Recruiting PHASE2 Osteoarthritis Hand

New treatment option for Osteoarthritis Hand

Official title Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis

ClinicalTrials.gov ID: NCT06034262

What this study is testing

What is SclerFIX-IP?

SclerFIX-IP is an investigational medicine, being studied as a potential treatment for osteoarthritis hand.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The aim of this open, prospective, multicenter trial is to evaluate the use of a sterile, devitalized, processed umbilical cord amniotic membrane implant placed in joint interposition in the treatment of PIP joint osteoarthritis.
  • Phase 2: a mid-size study of how well it works

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 75

You may be able to join if

  • Male or female; age between 18 and 75 years.
  • Patient with symptomatic PIPJ OA.
  • Patient treated medically for functional signs for more than 3 months, without improvement, justifying a surgical intervention.
  • Patient with a QuickDash score \> 33 points (converted to 50%).
  • Patient with pain, at rest, in the PIPJ ≥ 4/10 on a VAS.

You likely can't join if

  • Pregnant or breastfeeding woman; woman without effective contraception.
  • Patient with signs of neuropathy with functional disorders such as hyperesthesia.
  • Patient with uncontrolled epilepsy or neuropathy that contraindicates locoregional anesthesia.
  • Person confined by a judicial or administrative decision.
  • Adult subjected to legal protection measures or unable to provide his/her consent.
See the full eligibility criteria
Who can join
  • Male or female; age between 18 and 75 years.
  • Patient with symptomatic PIPJ OA.
  • Patient treated medically for functional signs for more than 3 months, without improvement, justifying a surgical intervention.
  • Patient with a QuickDash score \> 33 points (converted to 50%).
  • Patient with pain, at rest, in the PIPJ ≥ 4/10 on a VAS.
  • Patient who received the study information and provided consent.
  • Member or beneficiary of a national health insurance plan.
What rules you out
  • Pregnant or breastfeeding woman; woman without effective contraception.
  • Patient with signs of neuropathy with functional disorders such as hyperesthesia.
  • Patient with uncontrolled epilepsy or neuropathy that contraindicates locoregional anesthesia.
  • Person confined by a judicial or administrative decision.
  • Adult subjected to legal protection measures or unable to provide his/her consent.

The study team makes the final eligibility decision.

Where it's taking place

  • Besançon, France
  • Lyon, France
  • Nantes, France

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Besançon, France; Lyon, France; Nantes, France. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.